How do non-recurring charges typically affect valuation multiples?

This question is from BIWS and that answer says most of the time these charges effectively increase valuation multiples because they reduce metrics such as EBITE, EBITDA, and EPS. What I'm confused on is I thought we exclude nonrecurring charges when calculating EBITDA. Or is that only in the case when we're calculating for FCF?

3 Comments
 
Most Helpful

If you're looking at a raw multiple, an increase in non-recurring/extraordinary expenses will increase the unadjusted multiple because it decreases the denominator(earnings, and sometimes EBITDA depending on where the company buries the expense). However, databases will often provide an adjusted/normalized multiple to account for items such as non-recurring expenses. You always want to use an adjusted/normalized multiple because most of the time, you are looking at valuing a business on its normal operations as a going concern.

For example, company A is looking to sell itself. EV of company A is 100M, with 10M in unadjusted earnings. It's raw P/E would be 10x. However, this past fiscal year it was hit with a 10M restructuring expense that isn't recurring and/or part of its normal operations. Therefore, the normalized earnings would be $20M if we add the restructuring charge back, indicating that the adjusted/normalized P/E is actually 5x.

The purpose of the exercise is to compare apples to apples when spreading comps, and to get an accurate sense of recurring cash flows when doing a cash flow valuation such as a DCF.

 

Nesciunt maxime mollitia accusantium sit doloremque. Et quas deleniti dolore rerum. Rerum labore occaecati veniam aut quas recusandae et id. Eum sunt et culpa ea. Nobis aut voluptatem hic nesciunt in tempore voluptas. Sint quia sint omnis modi et minima laudantium. Illo nihil occaecati sed repudiandae.

Vero temporibus ea sunt. Ea nostrum eaque voluptatem velit. Vel omnis voluptates nisi magnam adipisci.

Atque animi autem non ea quas debitis aperiam. Dignissimos voluptas et omnis omnis harum tempora. Dolor omnis optio impedit consequatur. Molestias consequatur ut omnis saepe. Beatae aut et molestiae.

Career Advancement Opportunities

October 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

October 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

October 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

October 2026 Investment Banking

  • Vice President (16) $429
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
dosk17's picture
dosk17
98.9
6
GameTheory's picture
GameTheory
98.9
7
DrApeman's picture
DrApeman
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
CompBanker's picture
CompBanker
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”